Press Releases

Keyword Search
 
DateTitle 
11/13/17Jounce Therapeutics Reports Third Quarter 2017 Financial Results
- Remain on track to announce preliminary efficacy data for the Phase 1/2 ICONIC study in 1H 2018 - - Strengthen leadership team and board with key new appointments - - Update full year financial guidance - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers ... 
Printer Friendly Version
11/09/17Jounce Therapeutics to Present at the Stifel 2017 Healthcare Conference
CAMBRIDGE, Mass., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced that Richard Murray, Ph.D., chief executive officer and president of Jounce, will present at the Stifel 2017 Healthcare Conference at 8:00 a.m. ET on Tuesday, November 14, 2017 in New York. A live webcast of the presentation will be availab... 
Printer Friendly Version
11/08/17Jounce Therapeutics to Announce Third Quarter 2017 Financial Results and Host Conference Call on Monday, November 13, 2017
CAMBRIDGE, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced that it will report third quarter 2017 financial results on Monday, November 13, 2017. Jounce Therapeutics' management team will host a conference call and live audio webcast to discuss these results and provide a corporate update at 8:00 a.... 
Printer Friendly Version
11/07/17Jounce Therapeutics to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
Data Supports Biomarker-Driven Strategy for Development of ICOS Agonist Antibody, JTX-2011 CAMBRIDGE, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced that preclinical data supporting its Translational Science Platform and biomarker driven strategy will be presented during the pre-conference program... 
Printer Friendly Version
10/23/17Jounce Therapeutics Appoints Luis A. Diaz, Jr., M.D., to its Board of Directors
CAMBRIDGE, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced the appointment of Luis A. Diaz, Jr., M.D. to its board of directors. Dr. Diaz brings to the company his world-renowned expertise in cancer genetics and a precision medicine approach to immuno-oncology. “We are thrilled to welcome Luis to... 
Printer Friendly Version
08/30/17Jounce Therapeutics to Present at Upcoming Investor Conferences in September
CAMBRIDGE, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced that Richard Murray, Ph.D., chief executive officer of Jounce, will present at two upcoming investor conferences: Baird 2017 Global Healthcare Conference at 12:15 p.m. ET on Wednesday, September 6, 2017 in New York, NY 2017 Wells F... 
Printer Friendly Version
08/15/17Jounce Therapeutics Names Hugh Cole as Chief Business Officer and Head of Corporate Development
CAMBRIDGE, Mass., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced that Hugh Cole has been appointed as chief business officer and head of corporate development. He brings over 25 years of experience in biotech across business development, corporate strategy, R&D portfolio, program, and alliance managem... 
Printer Friendly Version
08/09/17Jounce Therapeutics Reports Second Quarter 2017 Financial Results
- Presented Phase 1 data from ICONIC study of JTX-2011 at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting - - Initiated Phase 2 portion of ICONIC study evaluating JTX-2011 in advanced solid tumors in both monotherapy and combination settings - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of ... 
Printer Friendly Version
08/02/17Jounce Therapeutics to Announce Second Quarter 2017 Financial Results and Host Conference Call on Wednesday, August 9, 2017
CAMBRIDGE, Mass., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies coupled with predictive biomarkers for patient enrichment, today announced that it will report second quarter 2017 financial results on Wednesday, August 9, 2017. Jounce Therapeutics' management team will host a conference call and live audio webcast to discuss these results and provide a corporate update ... 
Printer Friendly Version
06/05/17Jounce Therapeutics Presents Phase 1 Data from ICONIC Study of JTX-2011 in Patients with Advanced Solid Tumors at 2017 ASCO Annual Meeting
-- ICOS Agonist Antibody Well Tolerated Alone and as Combination Immunotherapy --   -- Phase 2 Monotherapy Cohorts Are Currently Enrolling Using ICOS Biomarker Patient Enrichment -- CAMBRIDGE, Mass., June 05, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced that Phase 1 data from the Company’s ICONIC study of JTX-... 
Printer Friendly Version
05/17/17Jounce Therapeutics to Present Phase 1 Data from JTX-2011 ICONIC Trial at 2017 American Society of Clinical Oncology Annual Meeting
Poster will be first presentation of clinical data with an ICOS agonist CAMBRIDGE, Mass., May 17, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced that safety and PK/PD data from its Phase 1 ICONIC Study of JTX-2011, an agonist monoclonal antibody targeting ICOS, will be presented in a poster presentation at the 20... 
Printer Friendly Version
05/09/17Jounce Therapeutics Reports First Quarter 2017 Financial Results
- Completed upsized initial public offering raising $117.1 million in gross proceeds - - Presented preclinical data supporting ongoing Phase 1/2 ICONIC study - - Initiated Phase 2 portion of ICONIC study evaluating JTX-2011 in advanced solid tumors - CAMBRIDGE, Mass., May 09, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies coupled with predictive biomarkers for patient enrichm... 
Printer Friendly Version
04/20/17Jounce Therapeutics Initiates Phase 2 Portion of ICONIC Study of JTX-2011 in Patients with Advanced Solid Tumors
Phase 1 Safety and PK/PD Data to be Presented at 2017 ASCO Annual Meeting CAMBRIDGE, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced enrollment of patients into the Phase 2 portion of the company’s Phase 1/2 ICONIC study of JTX-2011. JTX-2011 is a monoclonal antibody targeting ICOS, a protein foun... 
Printer Friendly Version
03/31/17Jounce Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes
CAMBRIDGE, Mass., March 31, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced that it has been added to the Russell 2000®, 3000® and Microcap® Indexes, effective March 31, 2017, as part of Russell’s quarterly additions of companies with recent initial public offerings. The Russell 2000® Index measures the performa... 
Printer Friendly Version
03/22/17Jounce Therapeutics to Present at AACR Annual Meeting on JTX-2011 Cancer Immunotherapy Program
-- Invited oral presentation on JTX-2011 preclinical data -- -- Poster presentation on single agent and combination trial design -- CAMBRIDGE, Mass., March 22, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies coupled with predictive biomarkers for patient enrichment, today announced it has been invited to present preclinical data that support the ongoing Phase 1/2 ICONIC trial... 
Printer Friendly Version
03/10/17Jounce Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
- Completed upsized initial public offering raising $117.1 million in gross proceeds -  - Continue to advance lead product candidate JTX-2011 through Phase 1/2 ICONIC trial and to broaden new drug candidate pipeline leveraging Translational Science Platform - CAMBRIDGE, Mass., March 10, 2017 (GLOBE NEWSWIRE) --  Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today repo... 
Printer Friendly Version
02/28/17Jounce Therapeutics to Present at Cowen and Company 37th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray, Ph.D., chief executive officer of Jounce, will present a company overview at the Cowen and Company 37th Annual Health Care Conference at 10:40 a.m. E.T. on Tuesday, March 7, 2017 in Boston.   A live webcast of the presentation will be avail... 
Printer Friendly Version
01/26/17Jounce Therapeutics Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass., Jan. 26, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc., a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the pricing of its initial public offering of 6,365,000 shares of common stock at a public offering price of $16.00 per share for aggregate gross proceeds of $101,840,000. In addition, Jounce granted the underwriters a 30-day option to purchase up to 954,750 additional shares o... 
Printer Friendly Version
DateTitle 
11/17/15Jounce Therapeutics Appoints Duncan Higgons to Its Board of Directors
... 
Printer Friendly Version
11/03/15Jounce Therapeutics Appoints Elizabeth Trehu, M.D., to Chief Medical Officer
... 
Printer Friendly Version
10/01/15Jounce Therapeutics Announces Presentation at the Leerink Partners Immuno-Oncology Roundtable
... 
Printer Friendly Version
09/15/15Jounce Therapeutics Appoints Kim Drapkin, CPA as Chief Financial Officer
... 
Printer Friendly Version
09/08/15Lasker Foundation Gives Jounce Founder, James Allison, 2015 Lasker Award
MARKING 70 YEARS, 2015 LASKER AWARDS HONOR SCIENTISTS FOR BASIC AND CLINICAL MEDICAL RESEARCH AND PUBLIC SERVICEEvelyn M. Witkin and Stephen J. Elledge for discoveries concerning the DNA-damage response—a fundamental mechanism that protects the genomes of all living organisms. James P. Allison for the discovery and development of a monoclonal antibody therapy that unleashes the immune system to combat cancer. Médecins Sans Frontières (Doctors Without Borders) for bold leadership in respo... 
Printer Friendly Version
05/05/15Jounce Therapeutics to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
... 
Printer Friendly Version
04/23/15Jounce Therapeutics Secures $56 Million in Oversubscribed Series B Financing
... 
Printer Friendly Version
04/15/15Jounce Therapeutics to Present at the Jefferies 2015 Immuno-Oncology Summit
... 
Printer Friendly Version
02/25/15Jounce Therapeutics to Present at the Cowen and Company 35th Annual Health Care Conference
... 
Printer Friendly Version
01/08/15Jounce Therapeutics Appoints Deborah Law, D. Phil., to Chief Scientific Officer
... 
Printer Friendly Version
01/06/15Jounce Therapeutics to Present at the J.P. Morgan Healthcare Conference
... 
Printer Friendly Version
DateTitle 
07/10/14Jounce Therapeutics Appoints Richard Murray, Ph.D., to Chief Executive Officer
... 
Printer Friendly Version
03/28/14Immunotherapy Innovator Wins 2014 Canada Gairdner International Award
... 
Printer Friendly Version
02/28/14Jounce Advisor Wins the AACR-CRI Lloyd J. Old Award in Cancer Immunology for Second Straight Year
... 
Printer Friendly Version
02/06/14Dr. James Allison of MD Anderson Cancer Center Awarded 2014 Szent-Györgyi Prize for Progress in Cancer Research
February 06, 2014 02:40 PM Eastern Standard Time BETHESDA, Md.--(BUSINESS WIRE)--The National Foundation for Cancer Research (NFCR) announced today that James Allison, Ph.D., Chairman, Department of Immunology at The University of Texas MD Anderson Cancer Center, has been awarded the 2014 Szent-Györgyi Prize for Progress in Cancer Research. Dr. Allison’s pioneering cancer research in the area of immunotherapy led to the successful development of “immune checkpoint therapy,” and the first FDA-app... 
Printer Friendly Version
01/09/14Adimab Announces New Partnerships with Jounce, Five Prime & Alector
... 
Printer Friendly Version
DateTitle 
12/13/13Jounce Co-Founder Dr. James Allison Wins Breakthrough Prize for Innovative Cancer Immunology Research
Public Release: 13-Dec-2013Discoveries in T cell biology, development of immune checkpoint blockade cancer therapy honoredUniversity of Texas M. D. Anderson Cancer CenterHOUSTON - Basic science research that exposed vital details of cancer's defense against the immune system, revealing an entirely new way to combat these diseases, has earned Jim Allison, Ph.D., a Breakthrough Prize in Life Sciences.Allison, chair of The University of Texas MD Anderson Cancer Center's Immunology department and ex... 
Printer Friendly Version
09/24/13Jounce Therapeutics Named a 2013 “Fierce 15” Biotech Company by FierceBiotech
... 
Printer Friendly Version
02/14/13Third Rock Ventures Launches Jounce Therapeutics with $47 Million Series A to Transform Cancer Treatment
... 
Printer Friendly Version